Letairis Uptake “Excellent” In First Full Quarter, Gilead Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the PAH drug, which competes with Actelion’s Tracleer, were around $6 million, but free-month offer is about to end.